‘Value through Innovation’ is the punch line used by the company known as Boehringer Ingelheim GmbH which was established during 1885 by the German chemist named Dr. Albert Boehringer, having its headquarters situated in Ingelheim, Germany, and is considered the international pharmaceutical corporation. The company is extensively engaged in developing various pharmaceuticals products for human use, biopharmaceuticals and animal health care. Nearly 95 percent of the company’s total sale is accrued through prescription and consumer health care products under the human pharmaceutical business, thus making that very sector the largest amongst all others.    

The company had initiated with the production of tartaric acid from wine yeast in small plant with the help of merely 20 employees, and presently after 120 years, the group ranks amongst the top 20 pharmaceutical enterprises of the world.  The company is the fastest developing enterprise in the pharmaceutical industry and is one of the biggest producers of biopharmaceuticals for industrial consumers of the world. The group has now almost 143 associate companies within and outside Germany.

The Research & Development wing of the group is mainly focusing on Human Pharmaceuticals which includes treatments for respiratory, cardiovascular, central nervous system-CNS, urology and viral disorders. Moreover, the company has also exaggerated its research activities into the sectors such as immune system, metabolism related ailments and cancer. Oncology is the latest addition in the group’s indication sectors.